June 28, 2024
4 min watch
Save
VIDEO: Three retinal therapies from Kodiak entering phase 3 studies
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Victor Perlroth, MD, CEO of Kodiak Sciences, provides an overview of the company’s ongoing retinal therapy programs.
“We now have three very compelling clinical assets that we are moving rapidly in multiple phase 3 studies this year,” he said.
Tarcocimab tedromer, the company’s lead molecule, was successful in earlier phase 3 studies in retinal vein occlusion, diabetic retinopathy and wet age-related macular degeneration, while KSI-501 is moving into a wet AMD study and KSI-101 is under investigation for macular edema secondary to inflammation.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Perlroth reports being CEO of Kodiak Sciences.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.